国产在线无码视频一区_免费看片A级毛片免费看_国产午夜福利精品一区二区三区_99久久人妻精品免费一区

您好, 歡迎來到化工儀器網

| 注冊| 產品展廳| 收藏該商鋪

13611715263

products

目錄:MedChemExpress LLC>>生化試劑>> Obinutuzumab | MCE

Obinutuzumab | MCE
  • Obinutuzumab | MCE
參考價 8100
具體成交價以合同協議為準
參考價 8100
具體成交價以合同協議為準
  • 品牌 MedChemExpress (MCE)
  • 型號
  • 廠商性質 生產商
  • 所在地 國外
屬性

$NV_PropertyInfoName.SubString(0,25)

>

更新時間:2023-06-08 11:36:46瀏覽次數:179評價

聯系我們時請說明是化工儀器網上看到的信息,謝謝!

同類優質產品

更多產品
CAS 949142-50-1 純度 ≥99.4%
分子量 146298.97 供貨周期 現貨
規格 5 mg 貨號 HY-P9910
應用領域 醫療衛生,化工,生物產業,制藥/生物制藥
Obinutuzumab | MCEObinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。

Obinutuzumab

CAS No. : 949142-50-1

產品活性:Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

研究領域:Immunology/Inflammation

作用靶點:CD20

In Vitro: Obinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab

In Vivo: Obinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies.

相關產品:Plamotamab  |  Glofitamab  |  Divozilimab  |  Mosunetuzumab  |  Ofatumumab  |  Ublituximab  |  Ripertamab  |  Blontuvetmab  |  Imvotamab  |  Rituximab (anti-CD20)  |  Zuberitamab  |  Odronextamab  |  Tositumomab  |  Ocaratuzumab

熱門產品線:重組蛋白  |  化合物庫  |  天然產物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質小分子活性化合物;
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
•   產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發、生命科學等科研項目;
•   提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業技術服務;
•   設有專業的實驗中心和嚴格的質控、驗證體系;
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
•   產品的生物活性多經各國客戶實驗驗證;
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
•   專業團隊跟蹤新的制藥及生命科學研究進展,為您提供*新的活性化合物;
•   與世界各大制藥公司及*科研機構建立了長期的合作。

類藥多樣性化合物庫
顧客使用MCE產品發表的科研文獻
一站式藥篩新體驗
MCE 您身邊的生物活性分子大師 | 抑制劑、激動劑、化合物庫
重組蛋白 | 高純度、高穩定性
磁珠

會員登錄

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

您的留言已提交成功!我們將在第一時間回復您~
在線留言

會員登錄

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:
熱線電話 在線詢價
主站蜘蛛池模板: 华容县| 大化| 泰和县| 肇东市| 新安县| 信丰县| 高雄市| 博乐市| 天气| 赣州市| 会泽县| 乌鲁木齐市| 新巴尔虎左旗| 桃源县| 成安县| 清苑县| 淮滨县| 天门市| 汉源县| 儋州市| 万年县| 大冶市| 阿图什市| 襄樊市| 临沧市| 分宜县| 沂源县| 威海市| 宜昌市| 林甸县| 牟定县| 肥乡县| 南投市| 永川市| 惠东县| 会宁县| 岑溪市| 玉溪市| 陕西省| 皋兰县| 墨玉县|